TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 176 filers reported holding TRAVERE THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 1.28 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $24 | -20.0% | 3,600 | -28.0% | 0.00% | -50.0% |
Q2 2023 | $30 | -31.8% | 5,000 | +150.0% | 0.00% | -20.0% |
Q1 2023 | $44 | +4.8% | 2,000 | 0.0% | 0.01% | +25.0% |
Q4 2022 | $42 | -99.9% | 2,000 | 0.0% | 0.00% | +33.3% |
Q3 2022 | $49,000 | +2.1% | 2,000 | 0.0% | 0.00% | 0.0% |
Q2 2022 | $48,000 | +380.0% | 2,000 | -73.3% | 0.00% | +200.0% |
Q1 2022 | $10,000 | +900.0% | 7,500 | -63.6% | 0.00% | – |
Q4 2021 | $1,000 | -83.3% | 20,600 | -4.2% | 0.00% | – |
Q3 2021 | $6,000 | – | 21,500 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Finepoint Capital LP | 1,028,875 | $25,351,000 | 8.34% |
GREAT POINT PARTNERS LLC | 966,108 | $23,805,000 | 5.73% |
Deep Track Capital, LP | 4,000,000 | $98,560,000 | 4.51% |
RA Capital Management | 4,922,941 | $121,301,000 | 2.59% |
ARMISTICE CAPITAL, LLC | 5,836,000 | $143,799,000 | 2.49% |
Kynam Capital Management, LP | 416,729 | $10,268,000 | 2.16% |
MPM BioImpact LLC | 276,460 | $6,812,000 | 1.61% |
HighVista Strategies LLC | 110,698 | $2,728,000 | 1.56% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 186,019 | $4,582,000 | 1.47% |
SECTORAL ASSET MANAGEMENT INC | 249,700 | $6,153,000 | 1.21% |